Thursday, November 05, 2020

Lineage Cell Therapeutics (LCTX)

Q3 2020 Earnings: OpRegen Data Update at AAO

Lineage Cell Therapeutics, Inc. (NYSE American: LCTX) is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer and in preclinical development for additional cancers and as a vaccine against infectious diseases, including SARS-CoV-2, the virus which causes COVID-19. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.

Ahu Demir, Ph. D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Nearest term catalyst: OpRegen data update at AAO. Lineage reported third quarter financial results On November 4, 2020. The company achieved multiple milestones and made progress on its three clinical programs. We believe the nearest term value generating catalyst for the company is the OpRegen program. The company will present updated interim results from the ongoing Phase 1/2a study of OpRegen at the 2020 American Academy of Ophthalmology Annual Meeting (AAO 2020) on November 15 and 17, 2020.

The company intends to step into oncology indications.  In addition to OpRegen, the company disclosed preliminary data from VAC2 in collaboration with Cancer Research UK (CR UK). Lineage will reacquire VAC2 to further develop the asset in the clinic and plans to initiate a Phase 1/2 clinical trial assessing VAC2 in non-small cell lung cancer or other indications in 2021 ...

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.